Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreat-ed, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) - Projekt - Autoren - KSSG Forschungsdatenbank

Projekt

Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreat-ed, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Laufend - Rekrutierung – beendet · 2020 bis 2029

Früh Martin

Früh, Martin

Stv. Chefarzt
Leitung Fachbereich Onkologie
Medizinische Onkologie und Hämatologie · Dept. I